Crossmark

Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study

Crossref DOI link: https://doi.org/10.1016/j.gastrohep.2021.04.010

Published Print: 2022-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Marín-Jiménez, Ignacio

Acosta, Manuel Barreiro-de

Esteve, María

Castro-Laria, Luisa

García-López, Santiago

Ceballos, Daniel

Echarri, Ana

Martín-Arranz, María Dolores

Busquets, David

Llaó, Jordina

Navarro-Llavat, Mercè

Huguet, José María

Argüelles-Arias, Federico

Vicente, Raquel

Boudet, José Miguel

Díaz, Gema

Sánchez-Migallón, Ana M.

Casellas, Francesc
Funding

Funding for this research was provided by:

AbbVie
License Information

Text and Data Mining valid from 2022-03-01

stm-asf valid from 2022-03-01

stm-asf valid from 2022-03-01

stm-asf valid from 2022-03-01

stm-asf valid from 2022-03-01

stm-asf valid from 2022-03-01
More Information

This article is maintained by: Elsevier

Article Title: Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study

Journal Title: Gastroenterología y Hepatología

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.gastrohep.2021.04.010

Content Type: article

Copyright: © 2021 Elsevier España, S.L.U. All rights reserved.